苯甲酸阿格列汀 T2401

Product Introduction
Bioactivity


英文名: Alogliptin Benzoate

描述: Alogliptin Benzoate (SYR 322) 是一种有效且特异性的 DPP-4 抑制剂 ，IC50值小于 10 nM，其选择性比 DPP-8/9 高 10,000 倍以上，可用于研究 2 型糖尿病。

体外活性: Alogliptin(SYR-322) is a potent inhibitor of DPP-4 and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9. Alogliptin is not an inhibitor of CYP-450 enzymes and does not block the hERG channel at concentrations up to 30 μM. [1]

体内活性: Alogliptin(SYR-322) produces dose-dependent improvements in glucose tolerance and increases plasma insulin levels in female Wistar fatty rats. [1] Acute administration of alogliptin results in a significant decrease in plasma DPP-4 activity, and increases plasma active GLP-1. Alogliptin improves glucose tolerance at a dose of 0.3 mg/kg and higher, with a dose-dependent increase in plasma IRI, suggesting that improved glucose tolerance results from the ability of alogliptin to enhance insulin secretion. [2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 63 mg/mL (136.5 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : 2 mg/mL (4.33 mM)


关键字: inhibit | Alogliptin Benzoate | SYR-322 | DPP | Alogliptin | diabetes | Ferroptosis | Dipeptidyl Peptidase | Inhibitor | DPP-4 | SYR322

相关产品: (E)-Ferulic acid | Alogliptin | Lapatinib | FA16 | Bardoxolone Methyl | Vildagliptin | ML-210 | FINO2 | SRS11-92 | BAY 87-2243

相关库: Drug Repurposing Compound Library | Approved Drug Library | HIF-1 Signaling Pathway Compound Library | Cell Cycle Compound Library | FDA-Approved & Pharmacopeia Drug Library | Ubiquitination Compound Library | Inhibitor Library | Highly Selective Inhibitor Library | EMA Approved Drug Library | Protease Inhibitor Library

苯甲酸阿格列汀 T2401信息由TargetMol中国为您提供，如您想了解更多关于苯甲酸阿格列汀 T2401报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途